Skip to main content

Simultaneous newborn screening for sickle cell disease, biotinidase deficiency, and hereditary tyrosinemia type 1 with an optimized tandem mass spectrometry protocol

This is a preview of subscription content, access via your institution.

Fig. 1

References

  1. Lobitz S, Klein J, Brose A, Blankenstein O, Frommel C (2019) Newborn screening by tandem mass spectrometry confirms the high prevalence of sickle cell disease among German newborns. Ann Hematol 98(1):47–53. https://doi.org/10.1007/s00277-018-3477-4

    CAS  Article  PubMed  Google Scholar 

  2. Brockow I, Blankenstein O, Breuer S, Ceglarek U, Ensenauer R, Gramer G, Janzen N, Klein J, Lankes E, Lindner M, Mirtschink P, Müller C, Murko S, Rönicke S, Röschinger W, Sommerburg O, Speckmann C, Nennstiel U (2021) National screening report 2019. https://www.screening-dgns.de/Pdf/Screeningreports/DGNS-Screeningreport-d_2019.pdf

  3. Heard GS, Wolf B, Jefferson LG, Weissbecker KA, Nance WE, McVoy JR, Napolitano A, Mitchell PL, Lambert FW, Linyear AS (1986) Neonatal screening for biotinidase deficiency: results of a 1-year pilot study. J Pediatr 108(1):40–46. https://doi.org/10.1016/s0022-3476(86)80766-1

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We are deeply indebted to all patients and their families who took part in this project. We are very grateful to “Kindness for Kids – Stiftung für Kinder mit Seltenen Erkrankungen” and “Eva Luise und Horst Köhler Stiftung” for their generous financial support. We thank SpOtOn Clinical Diagnostics for providing the reagents evaluated in this study free of charge.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephan Lobitz.

Ethics declarations

Ethics and consent

The ethical review committee of the Charité university hospital in Berlin approved the present study under the reference number EA2/126/17. All custodians gave written consent for the inclusion of their child into the study.

Competing interests

CT and ND are the directors of SpOtOn Clinical Diagnostics Limited. YD is named on the patent for the method referred to in the manuscript but has received no financial benefit. The other authors declare no conflict of interest.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lobitz, S., Frömmel, C., Brose, A. et al. Simultaneous newborn screening for sickle cell disease, biotinidase deficiency, and hereditary tyrosinemia type 1 with an optimized tandem mass spectrometry protocol. Ann Hematol 101, 1859–1860 (2022). https://doi.org/10.1007/s00277-022-04811-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04811-0